Trial of Umbilical and Foetal Flow in Europe: TRUFFLE study

ISRCTN ISRCTN56204499
DOI https://doi.org/10.1186/ISRCTN56204499
Secondary identifying numbers Lancet Protocol 02PRT/34
Submission date
04/06/2009
Registration date
27/08/2009
Last edited
11/03/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Mr Christoph Lees
Scientific

Centre for Fetal Care
Queen Charlotte’s and Chelsea Hospital
Imperial College Healthcare NHS Trust
Du Cane Road
London
W12 0HS
United Kingdom

Phone +44 (0) 20 8383 3998
Email Christoph.Lees@imperial.nhs.uk

Study information

Study designMulticentre three-armed randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeQuality of life
Participant information sheet Can be found at https://trufflestudy.org/truffle/docutruffle/TrufflePatientInformation.pdf
Scientific titleTrial of Umbilical and Foetal Flow in Europe: a multicentre three-armed randomised controlled trial
Study acronymTRUFFLE
Study objectives1. That among preterm growth-restricted babies, timing delivery when the foetal ductus venosus Doppler pulsatility index reaches the 95th centile increases the rate of normal infant neurodevelopmental outcome compared with delivery timing based on foetal heart short-term variation alone.
2. That among preterm growth-restricted babies, timing delivery when the foetal ductus venosus Doppler pulsatility index reaches a late stage of abnormality (a-wave reaching the baseline) increases the rate of normal infant neurodevelopmental outcome compared with delivery timing based on foetal heart short-term variation alone.
3. That among preterm growth-restricted babies, delaying delivery until the foetal ductus venosus Doppler pulsatility index reaches a late stage of abnormality (a-wave reaching the baseline) increases the rate of normal infant neurodevelopmental outcome compared with delivering when the foetal ductus venosus Doppler pulsatility index reaches the 95th centile.

On 28/01/2011 this record was updated to include the actual end date of the trial; the previous anticipated end date of this trial was 01/01/2010.

On 28/04/2014 the anticipated end date was changed to 31/12/2013 (end of follow-up).
Ethics approval(s)Multicentre Research Ethics Committee approved in September 2005 (ref: 05/Q0803/152). All other centres will obtain ethics approval prior to recruitment.
Health condition(s) or problem(s) studiedPregnancy/foetal growth restriction
InterventionThis is a randomised multicentre study of timing delivery in women in whom intrauterine growth restriction is found on ultrasound scan at gestations between 26 and 32 weeks. Trial entry is stratified by gestational age at enrolment. The intervention is delivery of the foetus, based on the criteria detailed below:
Group 1: control intervention, current standard of care: the timing of delivery is based on cardiotocography criteria for delivery, namely short-term variation below preset cut-offs based on gestation
Group 2a: delivery based on early ductus venosus changes (pulsatility index greater than 95th centile)
Group 2b: delivery based on late ductus venosus changes (a-wave reaches the baseline, i.e. 0 cm/s)
Intervention typeOther
Primary outcome measureSurvival without neurodevelopmental impairment at 2 years of age corrected for prematurity. Such impairment is defined as any of the following:
1. A standardised score of 70 or less on the Cognitive Scale from the Bayley Scale of Infant Development 3rd edition (i.e., more than 2 standard deviations below the mean)
2. Severe visual loss (legally certifiable as blind or partially sighted)
3. Cerebral palsy with a score of 2 or greater on the Gross Motor Function Classification System
4. Deafness requiring hearing aids
Secondary outcome measuresLong-term outcomes at 2 years age corrected for prematurity include:
1. The frequency of severe disability (Bayley score of 55 or less; severe cerebral palsy [Gross Motor Function classification systems - GMFCS] 4 or 5; blind; profound deafness)
2. Respiratory outcomes: days on home oxygen after discharge home, need for inhaled medications, hospital admissions
3. Weight, length, and head circumference (expressed as standard deviation scores)
4. Blood pressure
5. Other disability not classifiable as neurodevelopmental in origin
6. Survival analysis curves from study entry will be compared for a composite neonatal morbidity and mortality (to 28 days of life) and for mortality to 2 years, with hazard ratios and Cox's proportional model
7. Prespecified subgroup analyses include analysis by foetal sex, gestational age at delivery (less than 29 weeks; greater than 29 weeks) and indication for delivery
Overall study start date01/01/2005
Completion date31/12/2013

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants500
Key inclusion criteria1. The pregnancy should be singleton (i.e., not multiple pregnancy)
2. No obvious major structural abnormalities should have been identified on ultrasound
3. Certain menstrual age and/or ultrasound assessment of gestational age
4. The pregnancy should have reached at least 26 weeks gestation, but not yet 32 weeks of gestation by the time of recruitment
5. The ultrasound estimation of foetal weight should be at least 500 g at entry of the study
6. There should be ultrasound evidence of growth restriction, defined as a foetal abdominal circumference measurement under the 10th centile
7. Short term variability of the foetal heart rate after 1 hour recording should be greater than 3.5 beats per minute at 26 - 29 weeks, and greater than 4 beats per minute at 30 - 32 weeks
8. There should be evidence of abnormal umbilical artery bloodflow, manifesting as Umbilical arterial Doppler velocimetry above 95th centile
9. The foetal Ductus Venosus waveform using doppler ultrasound, should be normal defined as a venous pulsatility index under the 95th centile
10. There should be no obvious indication for immediate delivery (such as uncontrolled maternal high blood pressure)
11. The patient must be able to give informed consent to participation
Key exclusion criteriaDoes not meet inclusion criteria
Date of first enrolment01/01/2005
Date of final enrolment31/12/2013

Locations

Countries of recruitment

  • Austria
  • England
  • Germany
  • Italy
  • Netherlands
  • United Kingdom

Study participating centre

Centre for Fetal Care
London
W12 0HS
United Kingdom

Sponsor information

Addenbrooke's Hospital (UK)
Hospital/treatment centre

Research and Development Department
Cambridge
CB2 2QQ
England
United Kingdom

Website http://www.cuh.org.uk/addenbrookes/addenbrookes_index.html
ROR logo "ROR" https://ror.org/055vbxf86

Funders

Funder type

Research organisation

Dutch Council for Medical Research (Netherlands) - fully funding Dutch Centres

No information available

Central trial administration is funded through small donations, awards and proceeds from educational courses

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/10/2013 Yes No
Results article results 30/05/2015 Yes No